* Hoth Therapeutics Inc reported a quarterly adjusted loss of 46 cents per share for the quarter ended in March, higher than the same quarter last year, when the company reported EPS of -88 cents. The lone analyst forecast for the quarter was for a loss of 43 cents per share.
* Reported revenue was zero; analysts expected zero.
* Hoth Therapeutics Inc's reported EPS for the quarter was a loss of 46 cents.
* The company reported a quarterly loss of $2.04 million.
* Hoth Therapeutics Inc shares had fallen by 22.4% this quarter and lost 18.1% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 20.4% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the pharmaceuticals peer group is also "buy"
Wall Street's median 12-month price target for Hoth Therapeutics Inc is $4.00 This summary was machine generated from LSEG data May 15 at 09:51 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -0.43 -0.46 Missed
Dec. 31 2023 -0.51 -0.32 Beat
Sep. 30 2023 -0.72 -0.60 Beat
Jun. 30 2023 -1.16 -0.57 Beat
Comments